Pfizer leads the $53 million antibody drug into clinical practice

, which is focused on developing first-in-class immunomodulation antibodies, recently announced the completion of a $53 million (48 million euro) financing round B. The round of financing is co-led by Pfizer Ventures and Bpifrance, with Wellington Partners, Agent Capital and Alexandria Venture Investments involved. The company said the money will be used for clinical research into the treatment of solid tumors and blood cancers, mainly in research products.ImCheck Therapeutics was founded in 2015 and is headquartered in Marseille, France. The company is committed γ antibodies for the treatment of cancer and autoimmune diseases. ImCheck Therapeutics was originally split from Institut Paoli-Calmettes (IPC), Europe's leading cancer research centre, based on the research of Professor Daniel Olive. Professor Daniel Olive is a pioneer in the field of innant immunology and co-signaling molecules in Europe and the head of the IPC Early Oncology Clinical Trials Immunosuperance Program, as well as the scientific founder of ImCheck Therapeutics.Regarding the current round of financing, Mr. Pierre d'Epenoux, CEO of the company, said, "We will launch the first clinical trial of first-in-class monoclonal antibody ICT01 next year, which is based on comprehensive translational research and has the potential to activate gd T cells to kill malignant cells. Round B financing has enabled us to raise nearly $80 million over a two-and-a-half-year period, accelerating the development of our unique immuno-oncology pipeline and further expanding our research into antibodies in autoimmune diseases, while helping us with clinical operations and related research projects in the United States. ImCheck Therapeuticsstudy of tyrosine (BTN) super-family members targeting checkpoint molecules, according to the company's official website. ICT01 products are targeted at BTN3A, which is the primary activator of the cells. BTN3A is overexposed in a variety of solid tumors and blood cancers and is usually associated with good prognosis. In addition to the active antibody ICT01 used to treat cancer, ImCheck is also developing the antagonist antibody ICT21 for the treatment of autoimmune diseases.ImCheck's early preclinical pipeline includes therapeutic antibodies that target other members of the BTN/BTNL family and are designed to inhibit or activate different immune subsystresses, including the immune tumors (IO) and autoimmune diseases (AIDS).Dr. Michael Baran, Head of Pfizer Ventures and Executive Director of External Science and Innovation at Pfizer, said, "We believe that a better understanding of the biomass cell biomass may provide a strong research base for potential therapies for certain cancers and autoimmune diseases, and we are pleased to support ImCheck's research." "(Creative Exchange) is